About Neuraxpharm
Neuraxpharm is a Healthcare company based in Langenfeld (Germany) founded in 2009, and was acquired by Permira in September 2020. CNS drugs and treatments are developed and commercialized by Neuraxpharm. Neuraxpharm has completed 5 acquisitions, including Brain Therapeutics, Easypharm and FARMAX. Its chief executive, as recorded, is Jorg Thomas Dierks. Its website neuraxpharm.com draws about 79 thousand monthly visits. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Neuraxpharm Bohemia s.r.o.
Company details
Neuraxpharm was founded in 2009 and is headquartered in Langenfeld, Germany. Operations focus on the central nervous system sector, where established brands, value-added medicines, generics, consumer healthcare products, medical cannabis, digital health tools, medical devices, and orphan drugs are developed and commercialized. A broad portfolio of CNS treatment options is maintained to address patient needs across various conditions.
- Headquarters Langenfeld, Germany
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website neuraxpharm.com
- Acquired by Permira (Sep 2020)
- Legal Name Neuraxpharm Bohemia S.R.O.
- InvestorsPermira
& 1 more
- Investments & AcquisitionsBrain Therapeutics
& 4 more
- Acquired by
Investors in Neuraxpharm
Neuraxpharm has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Permira and Apax Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Equity investments are focused on tech, services, and consumer sectors. | 1981 | apax.com | Hong Kong, China | |
Investments are made in technology, consumer, healthcare, and service sectors. | 1985 | permira.com | London, United Kingdom |
Investor details for Neuraxpharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neuraxpharm
61 people are tracked at Neuraxpharm (35 in leadership, 26 in team).
| Name | Role | Group |
|---|---|---|
Jorg Thomas Dierks | CEO | Leadership |
Luboš Chadim | Managing Director Cz, Sk, H & East Europe Commercial Officer | Leadership |
Vikas Mohan Sharma | Chief Medical Officer | Leadership |
Mercedes Prior | Head Of Corporate Market Access | Leadership |
Francisco Jurado | Chief Scientific Officer | Leadership |
Lluís Pérez | Chief Financial Officer | Leadership |
Aida Fernandez | Chief Human Resources Offier | Leadership |
Stefan Hilbers | Head Of KAM | Leadership |
Miguel Barrero | Head, Business Development & Innovation | Leadership |
Tatiana Cantar | Corporate Head Accounting | Leadership |
Burghard Burczyk | Chief Technology Officer | Leadership |
Jörg-Thomas Dierks | Chief Executive Officer | Leadership |
Maximilian von Wülfing | COO | Leadership |
Inha Kim | Head Of Corporate Medical Affairs Neuroscience, Rare Disease | Leadership |
Ana Apezteguia | Chief of Staff | Leadership |
Alfredo Barón de Juan | General Manager, Cluster Head Spain, Portugal, Italy And Greece | Leadership |
Barbara Duhm | Country Manager/managing Director | Leadership |
Charles Morris | Head, Mergers & Acquisitions | Leadership |
Héctor López Palau | Senior Human Resources Business Partner | Leadership |
Riccardo Cerbai | Head Of Commercial | Leadership |
41 more people are available in the full profile.
Complete people profiles for Neuraxpharm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neuraxpharm
Neuraxpharm has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Brain Therapeutics, Easypharm and FARMAX.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Diversified pharmaceutical drugs are distributed across Brazil. | libberpharma.com.br | Barueri, Brazil | 2021 | Jun 2023 | •••• | |
Neurological services are offered at a standalone clinic in Athens. | braintherapeutics.gr | Athens, Greece | 2012 | Mar 2022 | •••• | |
Over-the-counter medicines are manufactured by Easypharm in Austria. | easypharm.at | Giebhubl, Austria | 2008 | Jan 2020 | •••• | |
Seed oil and organic seed cannabis services are provided. | hemplix.ch | Liestal, Switzerland | 2017 | Oct 2019 | •••• | |
Cloud-based software for livestock farm resource management is provided. | farmax.co.nz | Hamilton, New Zealand | 2003 | Feb 2019 | •••• |
Complete acquisition details for Neuraxpharm
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Neuraxpharm
8 dated milestones of Neuraxpharm across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Neuraxpharm is founded.
- Exit Acquired by Apax.
- Acquisition Acquires FARMAX.
- Acquisition Acquires Hemplix.
- Acquisition Acquires Easypharm.
- Exit Acquired by Permira.
- Acquisition Acquires Brain Therapeutics.
- Acquisition Acquires Libber Pharma.
Web traffic of Neuraxpharm
The website of Neuraxpharm (neuraxpharm.com) receives about 79.2K visits a month and ranks #506,953 among all websites worldwide, #507 in Biotechnology and Pharmaceuticals.
- Monthly visits79.2K
▲ 4.3% vs previous month
- Unique visitors33.8K
per month
- Global rank#506,953
among all websites
- Category rank#507
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.7
- Average visit28 sec
- DevicesDesktop 28% · Mobile 72%
Websites whose visitors overlap most with Neuraxpharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| farmaciamymed24.pt | 100% | 26.6K | #991,506 | View details | |
desitin.de | desitin.de | 91% | #1,396,435 | – | |
| apogepha.de | 91% | #2,803,767 | View details | ||
pharmafile.com | pharmafile.com | 91% | #2,442,969 | – | |
| ratiopharm.de | 91% | 631.1K | #116,712 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Neuraxpharm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neuraxpharm
Complete news archive for Neuraxpharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neuraxpharm
Neuraxpharm was founded in 2009.
Neuraxpharm is headquartered in Langenfeld, Germany. It is registered at Langenfeld, North Rhine-westphalia, Germany.
Jorg Thomas Dierks is the CEO of Neuraxpharm, as recorded in our data.
Neuraxpharm was founded in 2009 and is headquartered in Langenfeld, Germany. Operations focus on the central nervous system sector, where established brands, value-added medicines, generics, consumer healthcare products, medical cannabis, digital health tools, medical devices, and orphan drugs are developed and commercialized. A broad portfolio of CNS treatment options is maintained to address patient needs across various conditions.
Neuraxpharm has made 5 acquisitions, including Brain Therapeutics, Easypharm, and FARMAX.
Neuraxpharm has 2 investors. Key investors include Permira, and Apax Partners.
Neuraxpharm operates through Neuraxpharm Bohemia S.R.O..
Yes. Neuraxpharm was acquired by Permira in September 2020.